Arrowstreet Capital Limited Partnership Has $995.62 Million Holdings in McKesson Corporation $MCK

Key Points

• Arrowstreet Capital increased its stake in McKesson by 4.2% to 1,288,763 shares worth about $995.62 million, representing roughly 1.04% of the company and its 25th largest holding.
• McKesson beat quarterly expectations, reporting EPS of $9.34 on $106.16 billion revenue and setting FY2026 guidance of $38.80–$39.20 EPS; it also announced a $0.82 quarterly dividend (annual $3.28, yield ~0.3%).

Arrowstreet Capital Limited Partnership boosted its position in shares of McKesson Corporation (NYSE:MCK - Free Report) by 4.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,288,763 shares of the company's stock after purchasing an additional 52,227 shares during the period. McKesson comprises 0.6% of Arrowstreet Capital Limited Partnership's holdings, making the stock its 25th largest position. Arrowstreet Capital Limited Partnership owned approximately 1.04% of McKesson worth $995,621,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of MCK. GGM Financials LLC bought a new position in shares of McKesson during the third quarter worth about $25,000. State of Wyoming bought a new stake in McKesson in the 2nd quarter valued at approximately $29,000. Hopwood Financial Services Inc. bought a new stake in McKesson in the 3rd quarter valued at approximately $31,000. Abound Wealth Management boosted its position in McKesson by 104.3% during the 3rd quarter. Abound Wealth Management now owns 47 shares of the company's stock worth $37,000 after acquiring an additional 24 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new position in shares of McKesson during the 2nd quarter worth approximately $35,000. Institutional investors and hedge funds own 85.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MCK. Mizuho lifted their price objective on shares of McKesson from $880.00 to $885.00 and gave the company a "neutral" rating in a report on Thursday, February 5th. Weiss Ratings downgraded shares of McKesson from a "buy (a-)" rating to a "buy (b+)" rating in a research report on Thursday, February 5th. Raymond James Financial set a $970.00 price target on shares of McKesson in a research note on Thursday, March 5th. Barclays boosted their price target on shares of McKesson from $960.00 to $1,050.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Finally, Zacks Research downgraded shares of McKesson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 25th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $960.93.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Michele Lau sold 2,725 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the transaction, the executive vice president owned 3,247 shares of the company's stock, valued at $3,214,530. The trade was a 45.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Maria Martinez sold 349 shares of McKesson stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total value of $328,014.63. Following the transaction, the director owned 301 shares of the company's stock, valued at $282,900.87. This represents a 53.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,868 shares of company stock valued at $3,743,820 in the last three months. Corporate insiders own 0.08% of the company's stock.

McKesson Trading Up 1.0%

NYSE:MCK opened at $943.88 on Friday. The stock has a market capitalization of $115.62 billion, a PE ratio of 27.15, a P/E/G ratio of 1.50 and a beta of 0.38. McKesson Corporation has a 1-year low of $637.00 and a 1-year high of $999.00. The firm has a fifty day simple moving average of $891.54 and a 200 day simple moving average of $822.52.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. During the same period in the prior year, the firm posted $8.03 earnings per share. The company's quarterly revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson's dividend payout ratio (DPR) is 9.43%.

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.